# Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

> **NCT07061535** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 40 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Extensive Stage Lung Small Cell Cancer
- Extensive-Stage Small-Cell Lung Cancer
- Extensive Disease Small Cell Lung Cancer

## Interventions

- **DRUG:** Tafolecimab
- **DRUG:** Sintilimab (approved)
- **DRUG:** Etoposide
- **DRUG:** Carboplatin / Cisplatin

## Key facts

- **NCT ID:** NCT07061535
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07061535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07061535, "Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07061535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*